EUVIMEDEUVIMED entdecken
Open Access

Detecting Hyperglycemia Using Biomarkers Versus Continuous Glucose Monitoring

Natalie Rula Daya iD, Michael Fang iD, Jung-Im Shin iD, James S Pankow, Pamela L Lutsey, Arielle Valint, Justin B Echouffo-Tcheugui iD, Scott Zeger, Elizabeth Selvin iD

Diabetes Care · 01.08.2025 · 48 (8) · 1446-1452

DOI: 10.2337/dc25-0595 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 12.06.2025. Verfasst von Natalie Rula Daya und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, …. Hauptthemen laut MEDLINE: Hyperglycemia, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To evaluate the concordance of glycated albumin, fructosamine, 1,5-anhydroglucitol (1,5-AG), and hemoglobin A1c (HbA1c) with continuous glucose monitor (CGM) metrics of hyperglycemia and glycemic control in a diverse population of adults with type 2 diabetes. RESEARCH DESIGN AND METHODS This was a pooled cross-sectional analysis of 552 adults, ages 30–97 years old, with diabetes. Participants wore a CGM for up to 2 weeks, and we evaluated the agreement between blood biomarkers (glycated albumin, fructosamine, and 1,5-AG) with CGM-defined metrics of hyperglycemia and glycemic control. RESULTS Of the 552 participants (mean age 74 years, 53% women, 36% Black), the median of mean CGM glucose was 132 mg/dL, and participants spent on average 84% of their time in range (70–180 mg/dL). CGM mean glucose was strongly related to HbA1c (r = 0.72), glycated albumin (r = 0.64), and fructosamine (r = 0.64) but weakly related to 1,5-AG (r = 0.46). Results were similar for time above range (>180 mg/dL). Glycated albumin and fructosamine performed similarly to HbA1c in the detection of target time in and above range (c-statistics ranged from 0.85 to 0.94). CONCLUSIONS Glycated albumin and fructosamine had similar associations with CGM-defined metrics of hyperglycemia compared with HbA1c. These three biomarkers performed similarly in the detection of time above range and in range. Our results provide evidence for the utility of glycated albumin and fructosamine as alternate measures of hyperglycemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperglycemiaBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 2HumansFemaleMiddle AgedAgedFructosamineMaleAdultCross-Sectional StudiesGlycated HemoglobinBiomarkersAged, 80 and overSerum AlbuminDeoxyglucoseGlycated Serum AlbuminGlycation End Products, AdvancedContinuous Glucose Monitoring

Substanzen

FructosamineGlycated HemoglobinBiomarkersBlood GlucoseSerum AlbuminDeoxyglucose1,5-anhydroglucitolGlycated Serum AlbuminGlycation End Products, Advanced

Autor:innen und Institutionen

  • Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
  • Division of Epidemiology & Community Health, University of Minnesota School of Public Health, Minneapolis, MN.
  • University of North Carolina Gillings School of Public Health, Chapel Hill, NC.
  • Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

ORCID-Profile: Natalie Rula Daya, Michael Fang, Jung-Im Shin, Justin B Echouffo-Tcheugui, Elizabeth Selvin

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NIA NIH HHS
  • National Institute on Aging
  • National Heart, Lung, and Blood Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Daya, N. R., Fang, M., Shin, J. I., Pankow, J. S., Lutsey, P. L., Valint, A., Echouffo-Tcheugui, J. B., Zeger, S., & Selvin, E. (2025). Detecting Hyperglycemia Using Biomarkers Versus Continuous Glucose Monitoring. Diabetes Care, 48(8), 1446-1452. https://doi.org/10.2337/dc25-0595

Vancouver

Daya NR, Fang M, Shin JI, Pankow JS, Lutsey PL, Valint A, et al. Detecting Hyperglycemia Using Biomarkers Versus Continuous Glucose Monitoring. Diabetes Care. 2025;48(8):1446-1452. doi:10.2337/dc25-0595

BibTeX
@article{Daya2025,
  author = {Daya, Natalie Rula and Fang, Michael and Shin, Jung-Im and Pankow, James S and Lutsey, Pamela L and Valint, Arielle and Echouffo-Tcheugui, Justin B and Zeger, Scott and Selvin, Elizabeth},
  title = {Detecting Hyperglycemia Using Biomarkers Versus Continuous Glucose Monitoring},
  journal = {Diabetes Care},
  year = {2025},
  volume = {48},
  number = {8},
  pages = {1446--1452},
  doi = {10.2337/dc25-0595}
}
Kostenlos starten →